Abeona Therapeutics Inc
F:PCJP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abeona Therapeutics Inc
F:PCJP
|
US |
|
C
|
China Shenhua Energy Co Ltd
XHAM:IKF
|
CN |
|
C
|
Cintas Corp
XBER:CIT
|
US |
|
Rheinmetall AG
OTC:RNMBF
|
DE |
|
DSV A/S
LSE:0JN9
|
DK |
|
Freshpet Inc
NASDAQ:FRPT
|
US |
|
T
|
Toll Brothers Inc
LSE:0LFS
|
US |
Abeona Therapeutics Inc
Abeona Therapeutics is a biotechnology company focused on gene and cell therapies for rare genetic diseases. It tries to fix the underlying DNA problem behind a disorder, rather than just treating symptoms. Its work has centered on diseases that affect the eyes, the immune system, and other inherited conditions with very limited treatment options. The company develops these therapies in-house and works through the long drug-development path of testing, seeking approval, and then bringing a treatment to market. Its customers are not everyday consumers; they are specialist doctors, hospitals, treatment centers, and the insurers or government programs that pay for rare-disease medicines. Abeona can make money through product sales if a therapy reaches the market, and it may also use licensing or collaboration deals tied to its drug candidates. What makes Abeona different is its role at the very high-risk, highly specialized end of the healthcare value chain. Instead of selling broad-usage medicines, it focuses on one-time or limited-use treatments for small patient groups where the scientific challenge is hard but the medical need is large. That makes the business much more dependent on clinical results, regulatory approval, and access to rare-disease treatment centers than a normal drug company.
Abeona Therapeutics is a biotechnology company focused on gene and cell therapies for rare genetic diseases. It tries to fix the underlying DNA problem behind a disorder, rather than just treating symptoms. Its work has centered on diseases that affect the eyes, the immune system, and other inherited conditions with very limited treatment options.
The company develops these therapies in-house and works through the long drug-development path of testing, seeking approval, and then bringing a treatment to market. Its customers are not everyday consumers; they are specialist doctors, hospitals, treatment centers, and the insurers or government programs that pay for rare-disease medicines. Abeona can make money through product sales if a therapy reaches the market, and it may also use licensing or collaboration deals tied to its drug candidates.
What makes Abeona different is its role at the very high-risk, highly specialized end of the healthcare value chain. Instead of selling broad-usage medicines, it focuses on one-time or limited-use treatments for small patient groups where the scientific challenge is hard but the medical need is large. That makes the business much more dependent on clinical results, regulatory approval, and access to rare-disease treatment centers than a normal drug company.
Launch momentum: ZEVASKYN commercial launch resumed—2 patients treated since Q4 2025, 1 treated this quarter, 3 additional patients biopsied with more biopsies expected soon.
QTC footprint: Four qualified treatment centers (QTCs) are activated (2 treating, 2 in administrative/onboarding stages); company is working to onboard 5 more and aims for at least 7 QTCs by end of 2026.
Demand growth: Identified eligible patient pool expanded from ~50 to more than 100 after field team deployment; ~10 patients are advancing through administrative steps targeting Q2 2026 biopsies.
Payer coverage: Major commercial payers (UnitedHealthcare, Cigna, Aetna, Anthem and most BCBS plans) cover ZEVASKYN (~80% commercially covered lives); Medicaid baseline coverage across all 50 states and a permanent HCPCS J-code effective Jan 1, 2026.
Manufacturing capacity: Current facility cadence is 6 patients/month with a planned ramp to 10 patients/month later this year; manufacturing lead time is ~25 days per patient.
Financials snapshot: 2025 total revenue $5.8M (includes $2.4M net product revenue from the first commercial treatment and $3.4M license/other), net income $71.2M driven largely by a $152.4M gain from sale of a rare pediatric disease voucher; cash and short-term investments $191.4M as of 12/31/2025.
Profitability trigger: Management stated that roughly >3 patients/month (3.5+ mentioned) would move the company toward profitability versus an annual company burn around $100 million.
